I actually don't think it's going to be fun for you. Maybe in the short term, but this stock is so thin, it will only take 1 serious buyer to push this back up to $8-9. I read your other posts and QCOR really has nothing to do with RTRX. So they were both bidding on the same drug and QCOR won. Who cares? This has no impact on the rest of Retrophin's business. Also, they have enough cash in the bank to get to FONT3 data. If the data are positive, they will be able to raise post-data at $10-15/share. But do whatever you want, I will be steadily buying this for the next 6 months or so.
Yeah, go ahead to short an illiquid stock. That will be the ticket for you buddy. I am not sure Martin thinks he can win the bid, nor I think he wants to get into the whole ACTH business in the cheap. But one thing he has accomplished by not spending a dime is to further the public awareness of the price hikes QCOR did - from a few hundred dollars per vial to over $28,000 each now. The FTC will have fun to look over the QCOR-NVS deal, regardless how it is structured. With the latest SCOTUS ruling on pay for play (Big pharma - generics deal), I would think a close examination of the QCOR-NVS deal is not that far fetch. Plus, do anyone think QCOR mgmt. want to get a high visibility discussion about its pricing strategy? If Martin was successful to grab the synthetic ACTH and sell it at a couple hundred bucks per vial, QCOR would be trading in the teens now. But then again, Martin wasn't successful with his bid, so, what's next with this drama? My bet is some FTC, DOJ noise ahead, and who knows, maybe they won't let the deal through at all; meanwhile, more people know about the pricing practices over QCOR.